PlainRecalls
FDA Drug Moderate Class II Terminated

Metformin Hydrochloride Extended-Release Tablets, USP 750 mg a) 90 count (NDC 42291-611-90) b) 180 count (NDC 42291-611-18) c) 500 count (NDC 42291-611-50) bottles, Rx Only Manufactured for: AvKARE, Inc. Pulaski, TN 38478

Reported: June 24, 2020 Initiated: June 4, 2020 #D-1304-2020

Product Description

Metformin Hydrochloride Extended-Release Tablets, USP 750 mg a) 90 count (NDC 42291-611-90) b) 180 count (NDC 42291-611-18) c) 500 count (NDC 42291-611-50) bottles, Rx Only Manufactured for: AvKARE, Inc. Pulaski, TN 38478

Reason for Recall

CGMP Deviations: FDA analysis detected N-Nitrosodimethylamine (NDMA) impurity above the acceptable intake level

Details

Recalling Firm
AVKARE Inc.
Units Affected
88,545 bottles
Distribution
Nationwide.
Location
Pulaski, TN

Frequently Asked Questions

What product was recalled?
Metformin Hydrochloride Extended-Release Tablets, USP 750 mg a) 90 count (NDC 42291-611-90) b) 180 count (NDC 42291-611-18) c) 500 count (NDC 42291-611-50) bottles, Rx Only Manufactured for: AvKARE, Inc. Pulaski, TN 38478. Recalled by AVKARE Inc.. Units affected: 88,545 bottles.
Why was this product recalled?
CGMP Deviations: FDA analysis detected N-Nitrosodimethylamine (NDMA) impurity above the acceptable intake level
Which agency issued this recall?
This recall was issued by the FDA Drug on June 24, 2020. Severity: Moderate. Recall number: D-1304-2020.